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Abstract
 
Oxidative modification of LDL increases its atherogenicity,
and 15-lipoxygenase (15-LO) has been implicated in the
process. To address this issue, we generated transgenic rab-
bits that expressed 15-LO in a macrophage-specific manner
and studied their susceptibility to atherosclerosis develop-
ment when they were fed a high-fat, high-cholesterol
(HFHC) diet (Teklad 0533 rabbit diet 7009 with 10% corn
oil and 0.25% cholesterol) for 13.5 wk. Transgenic and non-
transgenic rabbits developed similar degrees of hypercholes-
terolemia and had similar levels of triglyceride, VLDL,
LDL, and HDL. Quantitative morphometric analysis of the
aortic atherosclerosis indicated that the transgenic animals
(
 
n 
 
5
 
 19) had significantly smaller lesion areas (9.8
 
6
 
6.5%,
mean
 
6
 
SD) than their littermate controls (
 
n 
 
5
 
 14, 17.8
 
6
 
15.0%) (
 
P 
 
,
 
 0.05). In a subgroup (
 
n 
 
5
 
 9) of transgenic rab-
bits that received the HFHC diet plus the antioxidant
 
N
 
9
 
,
 
N
 
9
 
-diphenyl-phenylenediamine (1%), the extent of lesion
involvement (9.8
 
6
 
7.5%) did not differ from the subgroup
(
 
n 
 
5
 
 10) that received the regular HFHC diet (9.7
 
6
 
5.9%).
Since the results were unexpected, we repeated the experi-
ments. Again, we found that the nontransgenic littermates
(
 
n 
 
5
 
 12) had more extensive lesions (11.6
 
6
 
10.6%) than the
transgenic rabbits (
 
n 
 
5
 
 13; 9.5
 
6
 
7.8%), although the differ-
ence was not significant. In a third set of experiments, we
crossed 15-LO transgenic rabbits with Watanabe heritable
hyperlipidemic (WHHL) rabbits and found that the lesion
area in the 15-LO transgenic/heterozygous WHHL rabbits
(
 
n 
 
5
 
 14) was only about one third (7.7
 
6
 
5.7%) that found
in nontransgenic heterozygous WHHL littermate controls
(
 
n 
 
5
 
 11, 20.7
 
6
 
19.4%) (
 
P 
 
,
 
 0.05). These data suggest that
overexpression of 15-LO in monocytes/macrophages pro-
tects against lipid deposition in the vessel wall during early
atherogenesis in these rabbit models of atherosclerosis. (
 
J.
Clin. Invest. 
 
1996. 98:2201–2208.)
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Introduction
 
There is evidence that oxidative modification of LDL in-
creases its atherogenicity (1, 2). LDL extracted from human
and rabbit atherosclerotic lesions has properties very similar to
oxidatively modified LDL (3). Two oxidation products, mal-
ondialdehyde and 4-hydroxynonenal–conjugated LDL, have
been demonstrated in rabbit atherosclerotic lesions by immu-
nochemical techniques (4, 5). Dietary supplementation of the
antioxidants probucol, butylated hydroxytoluene, or 
 
N
 
,'
 
N
 
'-
diphenyl-phenylenediamine to Watanabe heritable hyperlipi-
demic (WHHL)
 
1
 
 rabbits or normal rabbits fed a high choles-
terol diet inhibited the development of aortic atherosclerotic
lesions (6–9). Autoantibodies against oxidized LDL have been
detected in humans and, in one study, their titers show a posi-
tive correlation with the progression of carotid atherosclerosis
(10).
The mechanisms responsible for the oxidation of LDL in
vivo are not known. However, there is substantial evidence in-
dicating that 15-lipoxygenase (15-LO) plays a role (reviewed
in references 1, 2); in fact, many pharmaceutical companies
have been screening for 15-LO inhibitors as potential antiath-
erosclerosis agents, based on the widely held belief that 15-LO
is a proatherogenic molecule.
Although it is clear that 15-LO may represent one mecha-
nism for the oxidation of LDL, the relative contribution of
15-LO to LDL oxidation or to atherosclerosis development is
unknown. Furthermore, the presumed role of 15-LO in
atherogenesis has never been studied in vivo. To this end, we
have generated transgenic rabbits that express 15-LO in a
macrophage-specific manner. Two types of 15-LO transgenic
rabbits were studied, those with a wild-type New Zealand
white genetic background and those with a heterozygous
WHHL background. We examined the degree of aortic ath-
erosclerosis in response to a high fat, high cholesterol diet
feeding. To our surprise, we found that, compared with non-
transgenic littermate controls, the 15-LO transgenic rabbits
had a reduction in diet-induced aortic atherosclerosis as deter-
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mined by quantitative morphometry. Thus, contrary to popu-
lar belief, in these animals, the net overall effect of 15-LO ap-
pears to be antiatherogenic in nature.
 
Methods
 
Transgenic animal experiments. 
 
All animal experiments were per-
formed in accordance with Baylor College of Medicine institutional
guidelines. Transgenic rabbits were produced by a protocol described
previously (11). The transgene contains a 2.7-kb human 15-LO
cDNA (12), a generous gift from Dr. Elliott Sigal (Syntex, Palo Alto,
CA). A portion of the human apolipoprotein A-I gene containing the
5
 
9
 
-untranslated region and the first intron was ligated 5
 
9
 
 to the 15-LO
cDNA. This intron was included to enhance transgene expression.
This hybrid A-I/15-LO cDNA was inserted into a chicken lysozyme
genomic DNA containing 11.5-kb 5
 
9
 
- and 5.5-kb 3
 
9
 
-flanking se-
quences that include the A elements on both sides of the structural
gene (13). The donor and recipient rabbits were both New Zealand
white rabbits. The microinjection and subsequent screening were as
described (11). Positive animals were bred with wildtype New
Zealand white rabbits, and transmission of the transgene into the pro-
gency was determined by Southern blot analysis of ear DNA. Some
of the 15-LO transgenic rabbits were crossbred with WHHL rabbits
that had been derived from English half-lop rabbits (14). Transgenic
rabbits and their nontransgenic littermates were fed Diet A, a high
fat, high cholesterol diet (Teklad 0533 rabbit diet 7009 containing
10% corn oil and 0.25% cholesterol, Teklad Premier Laboratory Di-
ets, Madison, WI). In Experiment 1, a subgroup of transgenic rabbits
was fed Diet B, which is Diet A plus 1% 
 
N
 
9
 
,
 
N
 
9
 
-diphenyl-1,4-phen-
ylenediamine (DPPD). The DPPD was included to test the hypothe-
sis that it might inhibit the LDL-oxidizing effects of 15-LO. Each ani-
mal received 125 g of the chow per day for 13.5 wk. At different
times, blood was collected in EDTA tubes from the ear vein of anes-
thetized rabbits. Total cholesterol and triglyceride were determined
by enzymatic kits (Sigma Chemical Co., St. Louis, MO). Lipoprotein
fractions of different densities were isolated by sequential ultracen-
trifugal flotation (15) from 2 ml of plasma. The density of plasma was
sequentially adjusted by potassium bromide to isolate VLDL (
 
,
 
 1.006
g/ml), LDL (1.006–1.063 g/ml) and HDL (1.063–1.21 g/ml) by ultra-
centrifugation of the samples at 40,000 rpm in a 70.1 Ti rotor (Beck-
man Instruments, Inc., Fullerton, CA) at 10
 
8
 
C for 20, 24, and 48 h, re-
spectively. The cholesterol and triglyceride content of each fraction
was measured by enzymatic kits (Sigma Chemical Co.). The diet
feeding, plasma lipid/lipoprotein measurements, and isolation of rab-
bit aortas were performed at Baylor College of Medicine; the samples
were coded and sent to The Ohio State University for the morpho-
metric analyses by investigators (E. Herderick and J.F. Cornhill) who
were blinded to the identity of the treatment groups.
 
15-Lipoxygenase assay. 
 
15-LO activity was determined as de-
scribed previously (11). Briefly, peripheral monocytes were prepared
from transgenic and nontransgenic rabbits by Ficoll-Hypaque density
gradient centrifugation and adherence to plastic dishes (16). After
scraping from the dishes, the cells were resuspended in PBS (2–5 
 
3
 
10
 
6
 
 cells/ml) and exogenous arachidonic acid was added to a final
concentration of 160 
 
m
 
M. Incubation was for 15 min at 37
 
8
 
C. The re-
action was stopped by addition of equal volumes of a mixture of iso-
propanol/chloroform (1:1 by vol) and the lipids were extracted. The
extracts were dried under vacuum, the lipids were reconstituted in
100 
 
m
 
l of methanol, and the aliquots were injected to HPLC analysis
for quantitation of 15S-hydroxy-5,8,11,14(Z,Z,Z,E)-eicosatetraenoic
acid (15S-HETE) and 12S-hydroxy-5,8,10,14(Z,Z,E,Z)-eicosatet-
raenoic acid (12S-HETE) (11).
 
Quantitative morphometry of rabbit aortic atherosclerosis. 
 
The aor-
tas were fixed in 10% formalin and stained with Sudan IV (17). The
extent of sudanophilia was determined using image analysis tech-
niques employed previously to study the topographic distribution of
sudanophilic lesions in minipigs (18). These methods include image
capture, transformation of the data to a standard template, image
segmentation, and finally computation of probability-of-occurrence
maps. The images were scanned on an Eikonix 78⁄99 digital scanner at
a resolution of 2,048 
 
3
 
 256 pixels in 24-bit full color. A binary image
for each aorta was created by classifying each pixel of the scanned im-
age as Sudan positive or negative based on a supervised bayesian
color classification algorithm. Each binary image was transformed to
a standard template to remove anatomical variations among individu-
als. The standard template was created by calculating the average lo-
cation of anatomical landmarks for all individuals in the study. The
stored transformed binary images were then used to calculate proba-
bility-of-occurrence maps by computing the probability of finding a
Sudan-positive value at each pixel in the standard template. These
maps can be displayed as incidence interval isopleths (0–10%, 10–20%,
etc.). In addition, for each individual aorta, the percentage of Sudan-
positive area was computed by dividing the number of positive pixels
by the total number of pixels in the image. Using the Statistical Anal-
ysis System (SAS Institute, Cary, NC), a one-way ANOVA was per-
formed to test the hypothesis that there was no difference in the
mean percent-positive values between groups. The results are pre-
sented later in Table II.
 
HPLC analysis of linoleic acid oxidation. 
 
Cell preparation, incu-
bation, and analyses were carried out as described for the 15-lipoxy-
genase assay except that linoleic acid instead of arachidonic acid was
used as substrate. HPLC was carried out on a Shimadzu instrument
(Shimadzo Scientific Instruments, Inc., Columbia, MD) coupled with
a diode array detector (1040 A; Hewlett-Packard Co., Palo Alto,
CA). Reverse-phase HPLC was performed on a Nucleosil C-18 col-
umn (Macherey/Nagel, Bad Düren, Germany; KS-system, 250 
 
3
 
 4 mm,
5 
 
m
 
m particle size). A solvent system of methanol, water, and acetic
acid (85, 15, and 0.1 by vol, respectively) and a flow rate of 1 ml/min was
used. The fractions containing the oxygenated polyenoic fatty acids
were collected, the solvent was evaporated, the residue was reconsti-
tuted in a mixture of 
 
n
 
-hexane, 2-propanol, acetic acid (100, 2, and 0.1
by vol, respectively) and injected to straight-phase HPLC SIL column
(250 
 
3
 
 4.6 mm, 5 
 
m
 
m particle size; DuPont-Merck Pharmaceutical
Co., Wilmington, DE) with a solvent system of 
 
n
 
-hexane, 2-propanol,
and acetic acid (100, 2, and 0.1 by vol, respectively) and a flow rate of
1 ml/min. Fractions containing 13-hydroxy-9Z,11E-octadecadienoic
acid were collected, concentrated under vacuum, and enantiomer
composition determined by chiral-phase HPLC that was carried out
on a Chiralcel OD column (250 
 
3
 
 4.6 mm, 5 
 
m
 
m particle size; Diacel
Chemical Industries,
 
 
 
distributed by J.T. Baker, Deventer, The Neth-
erlands) with a solvent system of hexane, 2-propanol, and acetic acid
(100, 5, and 0.1 by vol, respectively) and a flow rate of 1 ml/min.
 
Results
 
Transgenic rabbits expressing human 15-LO. 
 
Previous studies
on the role of 15-LO in atherosclerosis have been confined to
in vitro analysis of 15-LO action or to correlative observations
on 15-LO expression and atherogenesis in animals or humans.
To determine more directly the role of 15-LO in atherosclero-
sis in vivo, we have produced transgenic rabbits (11) that over-
express human 15-LO (12). By Northern and Western blot
analysis, these animals express 15-LO in their monocyte-
derived macrophages, but not in any of the other tissues (liver,
uterus, lung, adrenal, brain, kidney, heart, muscle, small intes-
tine, and ovary) tested (11). The level of expression was high.
By incubating the monocyte-derived macrophages (prepared
as described in Methods) with exogenous arachidonic acid sub-
strate, transgenic macrophages produced 5.5
 
6
 
5.0 
 
m
 
g HETE
compared with 1.1
 
6
 
1.5 
 
m
 
g HETE per 10
 
7
 
 cells in controls,
 
P
 
 
 
,
 
 0.01. This level of 15-LO activity was comparable to that
of interleukin-4–treated human monocytes (19).
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High fat, high cholesterol diet feeding in 15-LO transgenic
rabbits with a wild-type New Zealand white background. 
 
We fed
the transgenic rabbits and their littermate controls a high fat,
high cholesterol (HFHC) diet containing 10% corn oil and
0.25% cholesterol without (Diet A) or with (Diet B) 1% DPPD
for 13.5 wk. Since Diet A– and Diet B–transgenic animals devel-
oped the same degree of hyperlipidemia, their lipid values are
considered together in Table I. The transgenic and nontrans-
genic animals developed comparable hypercholesterolemia
(Table I, Experiment 1). The plasma triglyceride remained un-
changed at 50.77
 
6
 
10.49 mg/dl (transgenic) and 55.83
 
6
 
13.37
mg/dl (nontransgenic) before diet treatment and 100.12
 
6
 
39.26
mg/dl (transgenic) and 112.88
 
6
 
45.37 mg/dl (nontransgenic) at
12 wk after diet treatment. The plasma VLDL, LDL, and
HDL cholesterol concentrations were also comparable in the
two groups of animals (Table I, Experiment 1).
After the animals were on the HFHC diet for 13.5 wk, they
were killed and the extent of aortic surface involvement with
atherosclerosis was determined by quantitative morphometry
(18). When stained with Sudan IV, the thoracic aortas of both
 
Table I. Cholesterol Concentration in Total Plasma and Lipoprotein Fractions
 
Cholesterol (mg/dl)
 
6
 
SD
Number VLDL LDL HDL Total plasma
 
Experiment 1: New Zealand white rabbits
Prediet
Transgenic 19 0.71
 
6
 
0.85 24.68
 
6
 
14.44 20.79
 
6
 
7.31 44.68
 
6
 
16.79
Nontransgenic 14 1.52
 
6
 
1.64 17.45
 
6
 
10.39 26.20
 
6
 
5.55 47.69
 
6
 
16.43
Week 12
Transgenic 19 224.01
 
6
 
63.14 244.93
 
6
 
60.86 32.65
 
6
 
12.63 865.92
 
6
 
247.86
Nontransgenic 14 225.11
 
6
 
35.48 222.26
 
6
 
57.32 35.34
 
6
 
13.57 931.16
 
6
 
184.13
Experiment 2: New Zealand white rabbits
Prediet
Transgenic 9 3.58
 
6
 
2.94 18.16
 
6
 
10.32 29.98
 
6
 
6.57 48.91
 
6
 
12.12
Nontransgenic 9 3.46
 
6
 
1.97 30.67
 
6
 
17.99 32.89
 
6
 
7.66 58.67
 
6
 
13.88
Week 12
Transgenic 13 234.22
 
6
 
78.21 231.34
 
6
 
83.60 61.25
 
6
 
19.09 704.00
 
6
 
376.64
Nontransgenic 12 286.04
 
6
 
38.27 301.34
 
6
 
100.85 70.69
 
6
 
20.49 810.60
 
6
 
298.98
Experiment 3: WHHL rabbits
Prediet
Transgenic 5 3.27
 
6
 
2.08 31.64
 
6
 
25.94 25.09
 
6
 
8.55 49.56621.50
Nontransgenic 3 4.4561.91 10.6465.55 26.48614.86 41.31619.63
Week 12
Transgenic 14 281.38675.94 341.646123.07 71.20647.95 726.776260.35
Nontransgenic 11 327.09623.29 399.546107.20 55.07626.68 875.836189.66
Lipids values determined at 4 and 8 wk also showed no difference between transgenic and nontransgenic animals (data not shown).
Table II. Aortic Atherosclerotic Lesion Involvement in 15-Lipoxygenase Transgenic Rabbits and Nontransgenic Littermate 
Controls
Number Lesion involvement percent6SD P value
Wild-type New Zealand white background
Experiment 1
Nontransgenic diet A 14 17.8615.0
Transgenic diet A 10 9.765.9 0.12 (vs nontransgenic)
Transgenic diet B 9 9.867.5 0.15 (vs nontransgenic)
Transgenic diet A1B 19 9.866.5 0.04 (vs nontransgenic)
Experiment 2 (diet A)
Nontransgenic 12 11.6610.6
Transgenic 13 9.567.8 0.57
Heterozygous WHHL genetic background
Experiment 3 (diet A)
WHHL-nontransgenic 11 20.7619.4
WHHL-transgenic 14 7.765.7 0.03
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Figure 1. Probability of occurrence of sudanophilia in the rabbit aorta. The method for the quantitative morphometry is as described in Methods. 
The maps for the nontransgenic and transgenic groups are displayed in banded incidence isopleths. The difference between the transgenic and 
nontransgenic groups is displayed at the bottom. The values in this difference map are computed by calculating at each pixel the difference be-
tween the nontransgenic and transgenic groups. Blue values indicate that the incidence in the nontransgenic group is greater than the corre-
sponding pixel in the transgenic group. Green values indicate the incidence is greater in the transgenic group. (A) Experiment 1: New Zealand 
white rabbits with (n 5 19) and without (n 5 14) the integrated human 15-LO transgene were studied. (B) Experiment 2: New Zealand white 
rabbits that were the progeny of those in Experiment 1 were used in this experiment a year later, after a rabbit breeding program. Number of an-
imals were: transgenic, 13; nontransgenic littermates, 12. (C) Experiment 3: heterozygous WHHL rabbits with (n 5 14) and without (n 5 11) the 
15-LO transgene obtained by crossbreeding were used in this experiment.
transgenic and nontransgenic rabbits showed heavy lesion in-
volvement. The abdominal aorta, in contrast, was generally
not as extensively covered by the lesions. It was, however,
much more extensively involved in the nontransgenic animals
compared with the transgenic group. The areas covered by
Sudan IV–positive atherosclerotic lesions are 17.8615.0% for
the nontransgenic group, 9.765.9% for the transgenic group
fed Diet A, and 9.867.5% for the transgenic group fed Diet B
(Diet A 1 1% DPPD). When the total combined transgenic
group lesion size was compared with that of the nontransgenic
animals, the difference was highly significant (P 5 0.04) (Table
II). The histology of the atherosclerotic lesions in the trans-
genic and nontransgenic groups of animals is very similar (data
not shown). All transgenic animals were combined for the
probability mapping analysis. The probability-of-occurrence
maps, Experiment 1 (Fig. 1 A), revealed that in both trans-
genic and nontransgenic animals, the highest probability of le-
sion formation occurred in the aortic arch area, especially on
the side of the greater curvature. In the abdominal aorta, in the
nontransgenic group, the area just distal to the mesenteric os-
tium showed a 20–40% probability of involvement, compared
with only a , 10–20% probability of a similar area in the trans-
genic group. The difference map at the bottom of Fig. 1 A con-
firms that the major difference in the probability of athero-
sclerotic lesion involvement occurs in the abdominal aorta
(different shades of blue in the figure). However, the probabil-
ity of occurrence is also greater in the aortic arch of the non-
transgenic animals. Throughout the entire surface area of the
aorta, the difference maps almost uniformly display areas of
equal or greater probability for the nontransgenic animals
compared with the transgenic animals. Only in a few scattered
areas is the converse (i.e., higher probability in the transgenic
group, green areas in the difference map) true.
It is evident in Table II that the presence of the human 15-LO
transgene was associated with an z 47% reduction in athero-
sclerosis involvement of the aorta. The inclusion of the antiox-
15-Lipoxygenase Transgene Protects against Atherosclerosis in Rabbits 2205
Figure 1. Continued.
idant DPPD in the diet did not change the degree of involve-
ment in the transgenic group. Thus, in this experiment,
macrophage-specific 15-LO overexpression was protective
against diet-induced atherosclerosis in New Zealand white
rabbits.
Because the results were totally unexpected, we decided to
repeat the experiment using another group of 15-LO trans-
genic rabbits and their littermate controls obtained by cross-
breeding. Again, in response to the HFHC Diet A feeding,
there was no difference in the total plasma or lipoprotein cho-
lesterol between the two groups of animals (Table I, Experi-
ment 2). The plasma triglyceride was 58.57621.84 mg/dl
(transgenic) and 54.85615.71 mg/dl (nontransgenic) before,
and 111.40680.54 mg/dl (transgenic) and 93.06643.15 mg/dl
(nontransgenic) at 12 wk of diet treatment. At the end of 13.5
wk, morphometric analysis of the rabbit aortas indicates that
there was a statistically insignificant reduction in the extent of
aortic atherosclerosis in the transgenic group (9.567.8%) com-
pared with the nontransgenic group (11.6610.6%) (Table II).
The probability maps, Experiment 2 (Fig. 1 B), revealed that
the aortic arch showed the highest probability of lesion in-
volvement. The difference map at the bottom of Fig. 1 B con-
firms that there were only minor differences in probability in
lesion involvement in the aortic arch and around the celiac and
mesenteric orifices. Blue areas slightly predominate over
green areas in this map, consistent with a slightly higher proba-
bility of lesion involvement in the nontransgenic group.
High fat, high cholesterol diet feeding in 15-LO transgenic
rabbits with a heterozygous WHHL genetic background. To fur-
ther define the role of 15-LO in atherosclerosis development
in an animal model of familial hypercholesterolemia, we inter-
crossed the 15-LO transgenic rabbits with WHHL rabbits.
Two groups of animals consisting of littermate heterozygous
WHHL rabbits, with and without the 15-LO transgene, were
fed the same HFHC Diet A for 13.5 wk. Again, there was no
difference in their total plasma cholesterol lipids in response to
the diet feeding. The plasma VLDL, LDL, and HDL choles-
terol were similar in the transgenic and nontransgenic WHHL
rabbits (Table I, Experiment 3) throughout the treatment pe-
riod. The plasma triglyceride was 55.54612.73 mg/dl (WHHL
transgenic) and 58.9467.94 mg/dl (WHHL nontransgenic)
before, and 41.43629.35 mg/dl (WHHL transgenic) and
40.21625.04 mg/dl (WHHL nontransgenic) at 12 wk after diet
treatment. (The data in the WHHL rabbits should not be com-
pared with those from Experiments 1 and 2 because the exper-
iments were performed at different times and the WHHL rab-
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bits were derived from a different strain [English half-lop
rabbits, reference 14].) When the size of the atherosclerotic le-
sion in the aortas of heterozygous WHHL rabbits with or with-
out an integrated 15-LO transgene was compared, it was clear
that the presence of the 15-LO transgene protected against the
development of atherosclerosis in these animals (Table II and
Experiment 3, Fig. 1 C). Although the general distribution of
lesions is similar in these WHHL rabbits compared with New
Zealand white rabbits, the probability-of-occurrence maps re-
veal some interesting differences (Fig. 1 C). As in wild-type
New Zealand white rabbits, the aortic arch of the nontrans-
genic heterozygous WHHL rabbit displays the highest proba-
bility of lesion involvement. This is followed by the areas
around the celiac, mesenteric, and renal ostia. In these non-
transgenic WHHL rabbits, there are areas of 30–40% lesion
probability in parts of the thoracic descending aorta. All these
areas were much less extensively involved in the 15-LO trans-
genic WHHL rabbit aortas. The difference map (Fig. 1 C, bot-
tom) shows blue and dark blue areas throughout the aortic
arch, the entire thoracic aorta and the proximal abdominal
aorta, in which there are substantially higher probabilities of
lesion involvement in the WHHL rabbits without the 15-LO
transgene compared with those with the transgene. Direct
quantitation of sudanophilic areas indicates that the nontrans-
genic WHHL aorta displayed a 20.7619.4% involvement,
which was reduced to about one third, or 7.765.7% involve-
ment (P 5 0.03), in the presence of the 15-LO transgene (Ta-
ble II). The results in Experiment 3 are thus quite consistent
with those in Experiment 1. Although the data in Experiment
2 showed a statistically insignificant protection by 15-LO, the
minor difference between transgenic and control animals was
in the same direction as in the other two experiments. Thus,
the combined results from all three experiments are consistent
with 15-LO having a protective effect on atherosclerosis devel-
opment.
Transgenic, but not nontransgenic, macrophages convert li-
noleic acid to 13-hydroxy-9,11(Z,E)-octacadienoic acid. When
linoleic acid was incubated with rabbit monocyte-derived mac-
rophages in vitro, only macrophages from 15-LO transgenic
rabbits, and not those from nontransgenic littermates, pro-
duced a 13-hydroxy-9,11(Z,E)-octadienoic acid (13-HODE)
product (Fig. 2).
Discussion
We initiated the 15-LO transgenic rabbit experiments because
of our belief that 15-LO was a proatherogenic molecule that
was responsible, at least partly, for the oxidative modification
of LDL. We used rabbits for these experiments because (a) the
Figure 1. Continued.
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size of these animals allowed us to repeatedly monitor the
plasma lipid and lipoprotein response; (b) many of the conclu-
sions on the atherogenic potential of 15-LO and oxidized lipo-
proteins were based on experiments performed in rabbits (3, 4,
6–9, 20, 21); (c) two of us (J.F. Cornhill and E. Herderick) have
developed a reliable method for quantitative morphometric
analysis of rabbit aortic atherosclerotic lesions (18); and (d)
the mouse, another popular animal model of atherosclerosis,
has 12-LO but no 15-LO and is thus not as suitable a model for
study. Three sets of experiments were performed consecu-
tively over a 3-yr period because of the time needed for cross-
breeding, diet feeding, and data analysis. The results of these
experiments (Fig. 1 and Table II) indicate that the presence of
the 15-LO transgene was associated with a reduction in the ex-
tent of diet-induced aortic atherosclerosis in the presence of
similar plasma lipid and lipoprotein levels (Table I). We be-
lieve that the results in the WHHL rabbits (Experiment 3) are
the most revealing. Here, the highly significant reduction in
atherosclerotic lesion involvement occurs in an animal model
of familial hypercholesterolemia.
Although unexpected, we do not believe that the observed
protective effect of 15-LO transgene expression in any way ne-
gates the hypothesis that oxidized LDL is much more athero-
genic than unoxidized LDL. Although there is still some con-
troversy regarding the exact mechanisms involved in LDL
oxidation (22, 23), there is general agreement that oxidized
LDL is a "harmful" molecule with regard to foam cell forma-
tion and atherosclerosis development. The explanation for the
antiatherogenic effect of the 15-LO transgene must lie else-
where.
One possibility for the experimental observations pre-
sented in this study is that 15-LO is totally uninvolved in the
oxidative modification of LDL. We do not believe that this is a
likely explanation because of the overwhelming evidence im-
plicating the enzyme in the oxidative process. The different
lines of evidence can be summarized as follows: (a) purified
15-LO can oxidatively modify LDL in cell-free systems (24,
25); (b) exposure of LDL to murine fibroblasts expressing high
levels of human 15-LO results in enhanced levels of lipoperox-
ides (26); (c) oxidation of LDL by cultured endothelial cells
and macrophages is inhibited in the presence of 15-LO inhibi-
tors (24, 27); (d) 15-LO mRNA and protein (20, 28) as well as
enzymatic activity (29) are expressed in macrophage-rich areas
of human and rabbit atherosclerotic tissues; (e) somatic gene
transfer of 15-LO into rabbit iliac arteries leads to the appear-
ance of oxidized LDL–specific epitopes (21); and (f) increased
amounts of stereospecific products of 15-LO-mediated oxida-
tion products have been demonstrated in early atherosclerotic
lesions in rabbits fed a high fat, high cholesterol diet (29). De-
spite the strong evidence implicating 15-LO in LDL oxidation,
the quantitative role of this enzyme in the process is unknown.
The design of the experiments on 15-LO transgenic rabbits
does not allow us to directly address the issue of whether
15-LO mediates LDL oxidation. In the face of the lines of evi-
dence for the involvement of 15-LO in the oxidative process
summarized above, we believe that other explanations for our
experimental results must be sought.
The explanation we favor is that 15-LO has multiple ac-
tions in vivo, some of which, like LDL oxidation, are pro-
atherogenic, whereas others may be antiatherogenic. The po-
tential antiatherogenic actions of 15-LO are unknown, but we
can speculate on some effects of the enzyme that may play a
role. 15-LO is known to convert linoleic acid, the predominant
essential fatty acid in the vessel wall, to 13-HODE (30). 13-
HODE is a platelet chemorepellant factor produced by endo-
thelial cells (31, 32) that inhibits platelet adhesion to these cells
(31–33). 13-HODE also stimulates prostacyclin production by
endothelial cells (34) and decreases thromboxane production
in platelets (35), effects that are antiatherogenic and anti-
thrombogenic. We have tested the capacity of transgenic and
control rabbit macrophages to produce 13-HODE from li-
noleic acid in vitro and found that this compound was the ma-
jor oxygenation product produced by transgenic macrophages,
but was not detectable with the nontransgenic macrophages
(Fig. 2). It has been proposed that the induction of 15-LO in
the atherosclerotic lesion may represent a protective response
(36). Thus, there could be other antiatherogenic effects of
15-LO that will be subjects of future investigations. In the
meantime, it is important to recognize that, in the transgenic
and control rabbits, the net overall effect of macrophage-medi-
ated 15-LO expression is not proatherogenic and may well be
protective. These observations have implications for the
pathogenesis of atherosclerosis; they also suggest that the
premise that specific 15-LO inhibitors are effective antiathero-
sclerotic pharmaceuticals needs reconsideration.
Figure 2. HPLC analysis of linoleic acid oxygenation products 
formed by peripheral monocyte-derived macrophages prepared from 
normal and transgenic rabbits. (A) Reverse phase–HPLC of products 
formed by monocyte-derived macrophages of nontransgenic rabbits. 
(B) Reverse phase–HPLC of products formed by monocyte-derived 
macrophages of nontransgenic rabbits; note the appearance of the 13-
HODE peak absent in A. (C) Straight phase–HPLC of products 
formed by monocyte-derived macrophages of transgenic rabbits. (D) 
Chiral phase–HPLC of products formed by monocyte-derived mac-
rophages of transgenic rabbits.
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